New Weight Loss Pill 2022

High-dose Wegovy leads to substantial weight loss in trial

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.

MarketWatch on MSN · 1d

Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,

Wall Street Journal · 1d

Wegovy at Higher Dose Achieves Greater Weight Loss in Trial

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.

STAT · 1d

High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.

Seeking Alpha on MSN · 1d

Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial

Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.

Medicare to negotiate prices for weight loss drugs

The Independent on MSN · 1d

Medicare announces 15 new drugs chosen for price negotiations, including popular weight loss drug Ozempic

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for the 15 additional drugs, which will be handled by the incoming administration, assure major savings for Americans.

The Washington Post on MSN · 1d

Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy, medications costing the massive government health program billions of dollars a year.

Hosted on MSN · 1d

Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

Becker's Hospital Review4d

New weight loss pill to be approved by early 2026: Eli Lilly

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13. The company is preparing to release key late ...

NBC New York5d

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the ...

Ibj.com8d

Lilly sees new weight-loss pill approval in early 2026, CEO says

Indianapolis-based Eli Lilly and Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, CEO Dave Ricks said, one of several in a new generation of the popular ...

Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results